- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05148845
Sisonke 2 - A COVID-19 Vaccine Boost Open Label Study. (Sisonke Boost)
Open-label, Single-arm Phase 3B Implementation Study to Evaluate the Effectiveness of the Homologous Boostof Ad26.COV2.S COVID-19 Vaccine Following the Prime Dose Among Sisonke Participants in South Africa(VAC31518COV30XX)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Purpose To evaluate the effectiveness and safety of the single dose Ad26.COV2.S (Jansen) COVID-19 vaccine plus a homologous boost with Ad26.COV2.S (Janssen) COVID-19 vaccine among Sisonke participants as compared to unboosted Sisonke participants
In addition the investigators will continue to evaluate VE of the Sisonke Boost compared to:
i) Vaccinated populations pre boosts ii) Unvaccinated populations in South Africa.
Study design Open-label, single-arm phase 3B vaccine implementation study
Rationale South Africa is severely affected by the global COVID-19 epidemic, and following the initial prime vaccination among HCWs in the first 4 months of 2021. New data has demonstrated the safety and effectiveness of a booster dose given two months or more after the initial Ad26.COV2.S. This provides the rationale and feasibility for the evaluation of a homologous booster vaccine dose to the cohort of vaccinated Sisonke participants to inform the larger vaccine rollout.
Study participants Sisonke participants age 18 and over working in the South African public and private health care sector (approx N=500 000) who were enrolled in Sisonke and have not subsequently had a further booster vaccine dose.
Study sites Department of Health Vaccine Administration Sites across South Africa supported by the Sisonke (Together) (VAC31518COV3012) Trial Research Site Investigators and Study Staff
Study duration Participants will receive a homologous Ad26.COV2.S (Janssen) booster dose of vaccine at least 6 months post the prime vaccination. The investigators will monitor outcomes utilising the DATCOV surveillance system and NHLS/NICD SARS COV-2 testing databases for up to 2 years post initial vaccination.
Study products Ad26.COV2.S by Janssen administered as a single dose followed by a single booster injection.
Primary objectives • To assess the effectiveness of Ad26.COV2.S vaccine as a homologous boost on severe COVID, hospitalizations and deaths in Sisonke participants as compared with the unboosted Sisonke populations.
Secondary objectives To assess the effectiveness of Ad26.COV2.S vaccine as a homologous boost on severe COVID, hospitalizations and deaths in Sisonke participants as compared vaccinated and unvaccinated populations of essential workers in South Africa.
- To estimate the incidence of symptomatic SARS CoV-2 infections in Sisonke participants following a boost compared with the unboosted Sisonke populations and general vaccinated and unvaccinated population in South Africa
- To estimate booster dose uptake among Sisonke participants in South Africa
- To monitor the genetic diversity of breakthrough SARS CoV-2 infections.
- To monitor safety in the case of homologous boosts in Sisonke participants.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Fatima Mayat, BPharm
- Phone Number: +2711 989 9798
- Email: mayatf@phru.co.za
Study Contact Backup
- Name: Ravindre Panchia, MBBCh
- Phone Number: +27 11 989 9700
- Email: panchiar@phru.co.za
Study Locations
-
-
-
Cape Town, South Africa, 7975
- Recruiting
- Desmond Tutu Health Foundation - Masiphumelele Research Office
-
Contact:
- Katherine M Gill, MBBCH
- Phone Number: +27(0) 21 785 3121
- Email: katherine.gill@hiv-research.org.za
-
Principal Investigator:
- KATHERINE M Gill, MBBCH
-
Rustenburg, South Africa, 0299
- Recruiting
- The Aurum Institute: Rustenburg Clinical Research Centre, Dr Lawrence
-
Contact:
- William L Brumskine, MBBCH
- Phone Number: +27(0) 87 135 1575
- Email: wbrumskine@auruminstitute.org
-
Principal Investigator:
- William L Brumskine, MBBCH
-
-
Eastern Cape
-
Mthatha, Eastern Cape, South Africa, 5100
- Recruiting
- Nelson Mandela Academic Clinical Research Unit (NeMACRU)
-
Contact:
- Dubula Thozama, MBBCH
- Phone Number: 074 502 1944
- Email: tdubula@witshealth.co.za
-
Principal Investigator:
- Thozama Dubula, MBBCH
-
Port Elizabeth, Eastern Cape, South Africa, 6001
- Recruiting
- Phoenix Pharma Pty Ltd
-
Contact:
- Daniel R Dr Malan, MBCHB
- Phone Number: +27 41 373 3832
- Email: iel.malan@phoenixpharma.co.za
-
Principal Investigator:
- Daniel R Malan, MBChB
-
Sub-Investigator:
- ZE E Punt, MBChB
-
-
Free State
-
Bloemfontein, Free State, South Africa, 9300
- Recruiting
- Josha Research
-
Contact:
- Johannes J Lombaard, MBBCH
- Phone Number: +27(0) 514 128 160
-
Principal Investigator:
- Johannes j Lombaard, MBBCH
-
-
Gauteng
-
Johannesburg, Gauteng, South Africa, 1862
- Recruiting
- Perinatal HIV Research Unit (PHRU), SOWETO
-
Contact:
- Erica Lazarus, MBBCH
- Phone Number: +27(0) 11 342 4075
- Email: lazaruse@phru.co.za
-
Sub-Investigator:
- Erica Lazarus, MBCHB
-
Johannesburg, Gauteng, South Africa, 2000
- Recruiting
- Clinical HIV Research Unit (CHRU),
-
Contact:
- Sharlaa Badal-Faesan, MBBCH
- Phone Number: +27(0) 11 276 8800
- Email: sfaesen@witshealth.co.za
-
Principal Investigator:
- Sharlaa Badal-faesan, MBBCh
-
Pretoria, Gauteng, South Africa, 0000
- Recruiting
- MeCRU Clinical Research Unit
-
Contact:
- Maposhane Nchabeleng, MBBCH
- Phone Number: 012 521 5667
- Email: maphoshane.nchabeleng@smu.ac.za
-
Pretoria, Gauteng, South Africa, 0152
- Recruiting
- Setshaba Research Centre,
-
Contact:
- Khatija K Ahmed, MBBCH
- Phone Number: 27(0) 12 799 2422
- Email: MMalahleha@setshaba.org.za
-
Sub-Investigator:
- Mookho Malahleha, MBBCH
-
Pretoria, Gauteng, South Africa, 2059
- Recruiting
- The Aurum Institute Clinical Research Centre, Pretoria
-
Contact:
- Coert Grobbelaar
-
Pretoria, Gauteng, South Africa
- Recruiting
- Ndlovu Research Centre
-
Contact:
- Rebone Maboa, MBBCH
- Phone Number: +27 13 983 8700
- Email: rmaboa@ndlovu.com
-
Principal Investigator:
- Maboa Rebone, MBBCH
-
-
Gauteng - South
-
Johannesburg, Gauteng - South, South Africa, 1632
- Recruiting
- The Aurum Institute: Tembisa Clinical Research Centre
-
Contact:
- Kathryn T Mngadi, MBBCH
- Phone Number: +27(0) 60 503 1870
- Email: kmngadi@auruminstitute.org
-
Principal Investigator:
- Kathryn Mngadi, MBBCH
-
Johannesburg, Gauteng - South, South Africa, 1809
- Recruiting
- Perinatal HIV Research Unit Kliptown
-
Contact:
- Erica M Lazarus, MBBCh
- Phone Number: 27(0) 11 342 4075
- Email: lazaruse@phru.co.za
-
Contact:
- Anusha Nana, BPharm
- Phone Number: 27(0) 11 342 4075
- Email: nanaa@phru.co.za
-
Principal Investigator:
- Erica Lazarus, MBBCH
-
-
KWA ZULU Natal
-
Bothas Hill, KWA ZULU Natal, South Africa, 3660
- Recruiting
- Botha's Hill Clinical Research Site
-
Contact:
- Elizabeth e Spooner, MBCHB
- Phone Number: +27(0) 31 777 1585
- Email: Elizabeth.Spooner@mrc.ac.za
-
Principal Investigator:
- Elizabeth E Spooner, MBCHB
-
Durban, KWA ZULU Natal, South Africa, 4001
- Recruiting
- CAPRISA eThekwini Clinical Research Site, Dr
-
Contact:
- Nivashnee Naicker
- Phone Number: +27(0) 31 655 0618
- Email: Nivashnee.naicker@caprisa.org
-
Principal Investigator:
- Nivashnee Naicker, MBBCH
-
Ladysmith, KWA ZULU Natal, South Africa, 3370
- Recruiting
- Qhakaza Mbokodo Research Clinic
-
Contact:
- Philippus L Kotze, MBBCH
- Phone Number: 27(0) 36 631 2372
- Email: plkotze@gmail.com
-
Principal Investigator:
- Philippus L Kotze, MBBCH
-
-
Kwa Zulu Natal
-
Durban, Kwa Zulu Natal, South Africa, 4030
- Recruiting
- Chatsworth Clinical Research Site
-
Contact:
- Logashvari Naidoo, MBBCH
- Phone Number: 27(0) 31 401 4150
-
Contact:
- Email: logashvari.naidoo@mrc.ac.za
-
Principal Investigator:
- Logashvari Naidoo, MBBCH
-
Durban, Kwa Zulu Natal, South Africa
- Recruiting
- CAPRISA Vulindlela Clinical Research Site, Dr Disebo Makhaza
-
Contact:
- Disebo Makhaza, MBBCH
-
Tongaat, Kwa Zulu Natal, South Africa, 4400
- Recruiting
- Tongaat Clinical Research Site, Dr
-
Contact:
- Vimla Naicker, MBCHB
- Phone Number: +27(0) 32 944 2208
- Email: vimla.naicker@mrc.ac.za
-
Principal Investigator:
- Vimla Naicker, MBCHB
-
-
Mpumalanga
-
Middleburg, Mpumalanga, South Africa, 1050
- Recruiting
- Mzansi Ethical Research Centre
-
Contact:
- Friedrich Petrick, MBBCH
- Phone Number: (013) 282 5218
-
Principal Investigator:
- Friedrich Petrich, MBBCH
-
-
North WEST Province
-
Klerksdorp, North WEST Province, South Africa, 2571
- Recruiting
- The Aurum Institute Klerksdorp Clinical Research Centre
-
Contact:
- James C Innes, MBBCH
- Phone Number: +27(0) 87 135 1616
- Email: cinnes@auruminstitute.org
-
Principal Investigator:
- James C Innes, MBBCH
-
-
Western CAPE
-
Cape Town, Western CAPE, South Africa, 7781
- Recruiting
- Emavundleni Research Centre
-
Contact:
- Scott Mahoney
- Phone Number: +27(0) 21 650 5851
- Email: lulu.nair@hiv-research.org.za
-
Principal Investigator:
- Scott Mahoney, MBBCH
-
-
Western Cape
-
Cape Town, Western Cape, South Africa, 7530
- Recruiting
- Task Clinical Research Centre
-
Contact:
- Andreas A Diacon, MBBCH
- Phone Number: +27 21 917 1044
- Email: ahd@task.org.za
-
Principal Investigator:
- Andreas A Diacon, MBBCH
-
Cape Town, Western Cape, South Africa, 7100
- Recruiting
- TASK Applied Science, Delft Day Hospital Premises
-
Contact:
- Andreas Diacon, MBBCH
-
Cape Town, Western Cape, South Africa, 7100
- Recruiting
- TASK Applied Science, Dr Ivans Toms Clinic Premises
-
Contact:
- Andreas Diacon, MBBCH
-
Cape Town, Western Cape, South Africa, 7505
- Recruiting
- FAMCRU (Family Clinical Research Unit),
-
Contact:
- Shaun L Barnabas, MBBCH
- Phone Number: 27(0) 21 938 4292
- Email: barnabas@sun.ac.za
-
Principal Investigator:
- S L Barnabas, MBBCH
-
Cape Town, Western Cape, South Africa, 7530
- Recruiting
- TASK Central
-
Contact:
- Andreas a Diacon, MBChB,
- Phone Number: +27(0) 21 100 3606
- Email: ahd@task.org.za
-
Principal Investigator:
- Andreas Diacon, MBChB
-
Cape Town, Western Cape, South Africa, 7925
- Recruiting
- Desmond Tutu Health Foundation CTU J52 Old Main Building Groote SchuurHospital
-
Contact:
- Sheetal Kassim, MBCHB
- Phone Number: +27(0) 21 406 6958
- Email: Sheetal.Kassim@hiv-research.org.za
-
Sub-Investigator:
- Catherine Orrell, MBChB,
-
Sub-Investigator:
- Richard Kaplan, MBChB
-
Sub-Investigator:
- F Cilliers, MBChB
-
Sub-Investigator:
- K Middelkoop, MBChB
-
Sub-Investigator:
- PK Chodacki, MBChB
-
Sub-Investigator:
- Y Singh, MB ChB
-
Cape town, Western Cape, South Africa, 7530
- Recruiting
- TASK Applied Science, Brooklyn Chest Hospital Premises
-
Contact:
- Andreas a Diacon, MBBCH
- Phone Number: : +27(0) 21 510 2209
- Email: ahd@task.org.za
-
George, Western Cape, South Africa, 6529
- Recruiting
- TASK Eden
-
Contact:
- Andreas Diacon, MBBCH
-
Worcester, Western Cape, South Africa, 6850
- Recruiting
- South African Vaccine Initiative (SATVI)
-
Contact:
- Angelique KK Luabeya
- Phone Number: +27(0) 23 346 5400
- Email: Angelique.luabeya@uct.ac.za
-
Principal Investigator:
- Angelique KK Luabeya, MBCHB
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Age 18 and older
- All Sisonke participants
- Received a priming Ad26.SARS.COV.2.S vaccination as part of the Sisonke study at least 6 months prior
- Participants who are pregnant or report breastfeeding at the time of enrolment may be included.
- Willingness and ability to comply with vaccination plan and other study procedures.
- Capable of giving electronic or personal signed informed consent as described in Appendix 5, which includes compliance with the requirements in this protocol.
Exclusion Criteria:
- Participants who have received boosting vaccination through other means.
- Any significant acute or chronic medical condition, situation or circumstance that in the opinion of the PI/designee makes the participant unsuitable for participation in the study, or jeopardises the safety or rights of the participant
- Current participation in any other research studies that would interfere with the objectives of this study. The determination of whether participation in another study would be exclusionary for a given participant will be made by the PI/designee.
- Participants with a history of heparin-induced thrombocytopenia or TTS
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess the effectiveness of Ad26.COV2.S (Janssen) boost vaccine on severe COVID, hospitalizations and deaths in Sisonke participants as compared to unboosted Sisonke participants (single Ad26 vaccine only)
Time Frame: 24 Months
|
Rates of hospitalizations and deaths among boosted Sisonke participants versus unboosted Sisonke participants and unvaccinated populations in South Africa
|
24 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess the effectiveness of Ad26.COV2.S (Janssen) boost vaccine on severe COVID, hospitalizations and deaths in Sisonke participants as compared to the vaccinated and unvaccinated populations (no vaccination) in South Africa.
Time Frame: 24 Months
|
Rates of hospitalizations and deaths among boosted Sisonke participants versus unboosted vaccinated and unvaccinated populations in South Africa
|
24 Months
|
To estimate the incidence of symptomatic SARS CoV-2 infections among boosted Sisonke ppts.
Time Frame: 24 months
|
Incidence rate of SARS CoV-2 infection as indicated by self-report and validation in national laboratory records. Rates of severe disease in Sisonke participants who are found to be RT-PCR positive at any time up to 2 years post prime vaccination |
24 months
|
To monitor the genetic diversity of breakthrough SARS CoV-2 infections
Time Frame: 24 Months
|
Genetic diversity of breakthrough infection virus as determined by whole genome sequencing.
This will be recovered from national laboratories.
|
24 Months
|
To estimate booster vaccine uptake among Sisonke participants in South Africa
Time Frame: 24 Months
|
Proportion of Sisonke participants approached for study participation taking part in the boost study and receiving the booster vaccine
|
24 Months
|
To monitor safety in homologous boosts
Time Frame: 24 Months
|
All SAEs and events of special interest will be collected and reported.
|
24 Months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Glenda Gray, MBChB, Non-Executive Director
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Sisonke Boost Open Label Study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
All study team scientists will disseminate the trial results as broadly as possible. Data will be shared with JNJ prior to release to the public. The study data will be published consistent with normal scientific practices.
The results from this research may also be disseminated through presentations at scientific institutions/ meetings, and/or publication in scientific journals. All publications will be uploaded to a publication repository. After sharing the results with study participants, they will be presented to communities from which participants are recruited, following Good Participatory Practice guidelines. The results will also be shared with global and local policy makers. Summary results of the trial will be made publicly available through the clinical trial registry. Any datasets used for analysis in publications can be requested by investigators via an online request to the organisation. Measures will be taken to protect identifiable information in the datasets
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Clinical Study Report (CSR)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on SARS CoV 2 Infection
-
St. Olavs HospitalThe Research Council of Norway; Helse Nord-Trøndelag HF; Alesund Hospital; Namsos... and other collaboratorsCompletedSARS-CoV-2 Acute Respiratory Disease | SARS-CoV-2 Sepsis | SARS CoV 2 InfectionNorway
-
Boston UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Burnet Institute and other collaboratorsRecruitingSARS CoV 2 Infection | SARS CoV 2 VaccinationUnited States, Malawi
-
Argorna Pharmaceuticals Co., LTDCompleted
-
Argorna Pharmaceuticals Co., LTDCompleted
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Active, not recruiting
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...Active, not recruiting
-
Arcturus Therapeutics, Inc.Terminated
-
University Hospital Inselspital, BerneUniversity of Bern; Lucerne University of Applied Sciences and ArtsCompleted
-
Centre Hospitalier Universitaire DijonUnknown
-
AIM Vaccine Co., Ltd.Zhejiang Provincial Center for Disease Control and PreventionNot yet recruiting
Clinical Trials on Booster vaccine
-
Tan Tock Seng HospitalKK Women's and Children's Hospital; Duke-NUS Graduate Medical School; A*StarRecruiting
-
Universidad del DesarrolloPontificia Universidad Catolica de Chile; University of Chile; Ministry of Health...Active, not recruiting
-
Laval UniversityCompletedHuman PapillomavirusCanada
-
University of California, San FranciscoActive, not recruitingCOVID-19 | Vaccine Reaction | COVID-19 PandemicUnited States
-
Bavarian NordicRecruitingChikungunya Virus InfectionUnited States
-
Seoul National University HospitalRecruitingRenal Transplant | COVID-19 VaccinationKorea, Republic of
-
Duke UniversityWashington University School of Medicine; University of Pittsburgh; Centers for... and other collaboratorsActive, not recruitingCOVID-19 | InfluenzaUnited States
-
National Taiwan University HospitalNational Science Council, TaiwanUnknownLiver Transplantation | Hepatitis BTaiwan
-
H. Lundbeck A/STerminatedAlzheimer DiseaseFinland, Sweden
-
Institute for Clinical and Experimental MedicineActive, not recruitingCOVID-19 | Kidney Diseases | Vaccine Adverse Reaction | Kidney Transplant; Complications | Rejection Acute Renal | Rejection Chronic RenalCzechia